Valuation: Altimmune Inc

Market Cap 558M 488M 450M 415M 782M 53.75B 799M 5.38B 2.12B 26.32B 2.1B 2.05B 90.62B P/E 2026 *
-4.26x
P/E 2027 * -3.79x
Enterprise Value 175M 153M 141M 130M 245M 16.86B 251M 1.69B 664M 8.26B 658M 643M 28.43B EV / Sales 2026 *
42,709x
EV / Sales 2027 * -
Free-Float
99.59%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 2025-12-31
Director of Finance/CFO 70 2024-11-10
Chief Tech/Sci/R&D Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 58 2003-08-31
Chairman 78 2017-12-31
Director/Board Member 76 2012-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-10.28%-43.79% - - 558M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -3.52%-2.62%+40.77%+183.80% 25.95B
Weighted average by Cap. -2.82%-2.36%+40.12%+144.11%

Financials

2026 *2027 *
Net sales 4.1K 3.58K 3.31K 3.05K 5.74K 395K 5.87K 39.52K 15.54K 193K 15.4K 15.06K 666K -
Net income -112M -97.69M -90.15M -83.09M -157M -10.77B -160M -1.08B -424M -5.27B -420M -411M -18.15B -139M -122M -112M -103M -195M -13.41B -199M -1.34B -528M -6.57B -523M -511M -22.6B
Net Debt -383M -335M -309M -285M -537M -36.89B -549M -3.69B -1.45B -18.07B -1.44B -1.41B -62.19B -256M -224M -206M -190M -359M -24.65B -367M -2.47B -970M -12.07B -961M -940M -41.56B
Logo Altimmune Inc
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-